77,496 Shares in Avanos Medical, Inc. (NYSE:AVNS) Bought by First Trust Advisors LP

First Trust Advisors LP acquired a new position in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 77,496 shares of the company's stock, valued at approximately $1,234,000. First Trust Advisors LP owned 0.17% of Avanos Medical at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Quantbot Technologies LP acquired a new position in Avanos Medical during the fourth quarter worth about $64,000. KLP Kapitalforvaltning AS acquired a new position in Avanos Medical in the 4th quarter valued at about $162,000. Mariner LLC grew its stake in Avanos Medical by 18.0% in the 4th quarter. Mariner LLC now owns 10,655 shares of the company's stock worth $170,000 after acquiring an additional 1,625 shares during the period. US Bancorp DE grew its stake in shares of Avanos Medical by 18.0% during the 4th quarter. US Bancorp DE now owns 14,093 shares of the company's stock valued at $224,000 after buying an additional 2,147 shares during the period. Finally, Pitcairn Co. lifted its holdings in shares of Avanos Medical by 13.6% during the 4th quarter. Pitcairn Co. now owns 17,290 shares of the company's stock valued at $275,000 after acquiring an additional 2,074 shares in the last quarter. 95.17% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the business's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares in the company, valued at approximately $1,251,216.75. The trade was a 7.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.64% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, StockNews.com raised Avanos Medical from a "hold" rating to a "buy" rating in a report on Wednesday, March 19th.

Avanos Medical Stock Performance

AVNS traded up $0.07 during trading hours on Friday, hitting $12.65. The company's stock had a trading volume of 406,766 shares, compared to its average volume of 348,361. The company has a 50-day simple moving average of $13.43 and a 200 day simple moving average of $16.03. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $581.94 million, a PE ratio of 37.21 and a beta of 1.13. Avanos Medical, Inc. has a fifty-two week low of $11.84 and a fifty-two week high of $25.36.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.07. The firm had revenue of $167.50 million during the quarter, compared to analyst estimates of $161.75 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. Avanos Medical's revenue was up .8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.22 EPS. As a group, sell-side analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current year.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.